UICMEW | Evaluation Questionnaire UICMEW | Evaluation We greatly value your opinion. Please complete this evaluation and submit it to the registration desk at the conclusion of this activity. Your responses will be used in future planning of activities and materials. Please select the conference attended: Please Select...Session 1: January 24, 2024 – GU, GI, and Thoracic OncologySession 2: January 31, 2024 – Women’s Cancers – Year in ReviewSession 3: February 7, 2024 – Hematologic Malignancies – Update from ASH I am a: * MD DO PharmD/RPh RN NP NP OtherOther Specialty * Upon completion of this activity, participants will be able to: Participants will be able to evaluate the efficacy and safety of using PARP inhibitors in managing HRR- mutated metastatic prostate cancer, including potential side effects and monitoring parameters. * Strongly Agree Agree Disagree Strongly Disagree Participants will be able to review the latest guidelines and recommendations for peri-operative therapy in localized rectal cancer. * Strongly Agree Agree Disagree Strongly Disagree Participants will identify the role and significance of biomarkers in early and advanced-stage non-small cell lung cancer. * Strongly Agree Agree Disagree Strongly Disagree Upon completion of this activity, participants will be able to: Discuss current and future roles of newly approved targeted therapies in all breast cancer subtypes. * Strongly Agree Agree Disagree Strongly Disagree Understand the side effects of practice-changing novel therapies and their integration into community practice. * Strongly Agree Agree Disagree Strongly Disagree Discuss emerging strategies for patients with platinum-resistant ovarian cancer. * Strongly Agree Agree Disagree Strongly Disagree Upon completion of this activity, participants will be able to: Discuss the optimal strategies for the use of CAR T Cell and bispecific T-cell engagers in Diffuse Large B Cell Lymphoma. * Strongly Agree Agree Disagree Strongly Disagree Explain how to optimize treatment selection in Multiple Myeloma, including the use of bispecific T- Cell engagers. * Strongly Agree Agree Disagree Strongly Disagree Identify novel treatment approaches in Acute Lymphoblastic and Acute Myeloid Leukemia. * Strongly Agree Agree Disagree Strongly Disagree Please indicate the extent of your agreement with the following statements: The faculty for this activity were effective. * Strongly Agree Agree Disagree Strongly Disagree The education resources and/or handouts provided to me at the educational activity are useful to my practice. * Strongly Agree Agree Disagree Strongly Disagree Not Applicable Overall, was this fair, balanced and free from commercial bias? * Yes No (Explain):No (Explain): Of the patients you will see in the next week, about how many will benefit from the information you learned today? * More than 50 26 to 50 11 to 25 1 to 10 Not applicable Based on what I learned today, I will improve my practice by incorporating the following (check all that apply): * Improved diagnosis/patient assessment Useful therapies and appropriate uses Cutting-edge science in this therapeutic area Best practices of my colleagues and leaders I do not plan to make any changes to my practice at this time Other (Explain):Other (Explain): Which ONE delivery method do you find the most effective for CME/CE learning? * Live symposia at national/regional conferences Live local meetings Live grand rounds Internet webcasts Internet/print monographs Other (Explain):Other (Explain): Please rate the professional practice value of each of the following in terms of improving your practice: Today's CME event: * Most Valuable Valuable Somewhat Valuable Least Valuable Direct to consumer advertising: * Most Valuable Valuable Somewhat Valuable Least Valuable Sales representative visits: * Most Valuable Valuable Somewhat Valuable Least Valuable Promotional/other non-certified education: * Most Valuable Valuable Somewhat Valuable Least Valuable Based on your experience, which of the following are the primary barriers to implementing changes in practice (check all that apply): * Lack of knowledge regarding evidence-based strategies Lack of convincing evidence to warrant change Lack of time/resources to consider change Insurance, reimbursement or legal issues Patient adherence/resistance to change Other (Explain):Other (Explain): What motivated you to participate in this activity? (check all that apply) * CME Credits Faculty Topic or Therapeutic area Format Type Other Comments: (Please include 1-3 case-based Questions) Submit If you are human, leave this field blank. Δ